$USCTF
Roth CH Acquisition Co. Stock $usctf

$usctf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000182912624002417 Filed on April 11, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$319.3K	$4.417M
YoY Change	-74.79%	89.09%
Operating Profit		-$4.417M
YoY Change		89.09%
Interest Expense	$180.4K	$125.0K
YoY Change	-94.1%	-99.08%
% of Operating Profit
Other Income/Expense, Net	$1.380M	-$73.43K
YoY Change	28.4%	-100.72%
Pretax Income	$1.241M	$2.587M
YoY Change	-30.78%	-77.0%
Income Tax
% Of Pretax Income
Net Earnings	$1.241M	$2.587M
YoY Change	-30.78%	-77.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$1.12	$2.34
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.76K	$13.76K
YoY Change	-88.92%	-88.92%
Cash & Equivalents	$13.76K
Short-Term Investments
Other Short-Term Assets	$38.14K	$38.14K
YoY Change	-88.65%	-88.65%
Inventory
Prepaid Expenses	$38.14K
Receivables
Other Receivables
Total Short-Term Assets	$51.90K	$51.90K
YoY Change	-88.73%	-88.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$23.33M	$23.33M
YoY Change	-90.2%	-90.2%
Other Assets
YoY Change
Total Long-Term Assets	$23.48M	$23.48M
YoY Change	-90.13%	-90.13%
TOTAL ASSETS
Total Short-Term Assets	$51.90K	$51.90K
Total Long-Term Assets	$23.48M	$23.48M
Total Assets	$23.53M	$23.53M
YoY Change	-90.13%	-90.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$661.0K	$661.0K
YoY Change	-58.21%	-58.21%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$682.5K	$682.5K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.343M	$1.343M
YoY Change	-19.05%	-19.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$556.3K	$556.3K
YoY Change	-94.01%	-94.01%
Total Long-Term Liabilities	$556.3K	$556.3K
YoY Change	-94.01%	-94.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.343M	$1.343M
Total Long-Term Liabilities	$556.3K	$556.3K
Total Liabilities	$1.900M	$1.900M
YoY Change	-82.64%	-82.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.956M
YoY Change	-14.56%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.848M	$21.63M
YoY Change
Total Liabilities & Shareholders Equity	$23.53M	$23.53M
YoY Change	-90.13%	-90.13%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$1.241M	$2.587M
YoY Change	-30.78%	-77.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$198.3K	-$863.0K
YoY Change	22.53%	42.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$180.0K	$217.2M
YoY Change
Cash From Investing Activities	-$180.0K	$217.2M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.6K	-$216.4M
YoY Change		1077385.44%
NET CHANGE
Cash From Operating Activities	-198.3K	-$863.0K
Cash From Investing Activities	-180.0K	$217.2M
Cash From Financing Activities	300.6K	-$216.4M
Net Change In Cash	-77.77K	-$110.5K
YoY Change	-51.96%	-82.36%
FREE CASH FLOW
Cash From Operating Activities	-$198.3K	-$863.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001860514
CY2023Q4	USCTU	Accrued Offering Costs AccruedOfferingCosts		usd
CY2022Q4	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty		usd
CY2023Q4	USCTU	Deferred Underwriter Fee Payable DeferredUnderwriterFeePayable		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2023	USCTU	Conversion Of Class B Ordinary Shares To Class Ordinary Shares ConversionOfClassBOrdinarySharesToClassOrdinaryShares		usd
CY2022	USCTU	Forgiveness Of Debt ForgivenessOfDebt		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2022	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts		usd
CY2022	USCTU	Investment Of Cash Into Trust InvestmentOfCashIntoTrust		usd
CY2022	USCTU	Payments For Redemptions Of Class Ordinary Shares PaymentsForRedemptionsOfClassOrdinaryShares		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	USCTU	Advances From Related Party AdvancesFromRelatedParty		usd
CY2022	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	USCTU	Payments For Redemption Of Class Ordinary Shares PaymentsForRedemptionOfClassOrdinaryShares		usd
CY2022	USCTU	Reduction Of Deferred Underwriting Fee Payable ReductionOfDeferredUnderwritingFeePayable		usd
CY2022	USCTU	Forgiveness Of Advances From Related Parties ForgivenessOfAdvancesFromRelatedParties		usd
CY2022	USCTU	Conversion Of Advances And Shortterm Promissory Notes To Longterm Promissory Notes ConversionOfAdvancesAndShorttermPromissoryNotesToLongtermPromissoryNotes		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	26600000	usd
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	East Hanover, NJ
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023Q4	us-gaap	Cash Cash	13755	usd
CY2022Q4	us-gaap	Cash Cash	124237	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38141	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	336075	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	51896	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	460312	usd
CY2023Q4	USCTU	Trust Account Receivable TrustAccountReceivable	147410	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23332031	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	237987827	usd
CY2023Q4	us-gaap	Assets Assets	23531337	usd
CY2022Q4	us-gaap	Assets Assets	238448139	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	660952	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1581635	usd
CY2022Q4	USCTU	Accrued Offering Costs AccruedOfferingCosts	78000	usd
CY2023Q4	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	682508	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1343460	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1659635	usd
CY2023Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	556250	usd
CY2022Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	482825	usd
CY2022Q4	USCTU	Deferred Underwriter Fee Payable DeferredUnderwriterFeePayable	8800000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1899710	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10942460	usd
CY2023Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	23479441	usd
CY2022Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	237987827	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7107564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8955953	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10482723	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1847814	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10482148	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23531337	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238448139	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4416661	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2335719	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4416661	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2335719	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	73425	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10197175	usd
CY2023	USCTU	Forgiveness Of Debt ForgivenessOfDebt	4692176	usd
CY2023	us-gaap	Interest Expense InterestExpense	125000	usd
CY2023	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	2509662	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3383885	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7003413	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	13581060	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2586752	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11245341	usd
CY2023	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Ordinary Redeemable Shares BasicAndDilutedWeightedAverageSharesOutstandingClassOrdinaryRedeemableShares	5323369	shares
CY2022	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Ordinary Redeemable Shares BasicAndDilutedWeightedAverageSharesOutstandingClassOrdinaryRedeemableShares	23000000	shares
CY2023	USCTU	Basic And Diluted Net Income Per Share Class Ordinary Redeemable Shares BasicAndDilutedNetIncomePerShareClassOrdinaryRedeemableShares	0.23
CY2022	USCTU	Basic And Diluted Net Income Per Share Class Ordinary Redeemable Shares BasicAndDilutedNetIncomePerShareClassOrdinaryRedeemableShares	0.39
CY2023	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Ordinary Nonredeemable Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBOrdinaryNonredeemableShares	5750000	shares
CY2022	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Ordinary Nonredeemable Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBOrdinaryNonredeemableShares	5750000	shares
CY2023	USCTU	Basic And Diluted Net Income Per Share Class And B Ordinary Non Redeemable Shares BasicAndDilutedNetIncomePerShareClassAndBOrdinaryNonRedeemableShares	0.23
CY2022	USCTU	Basic And Diluted Net Income Per Share Class And B Ordinary Non Redeemable Shares BasicAndDilutedNetIncomePerShareClassAndBOrdinaryNonRedeemableShares	0.39
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-18339662	usd
CY2022	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-3387827	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11245341	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10482148	usd
CY2023	USCTU	Sale Of Founder Shares And Private Warrants By Sponsor SaleOfFounderSharesAndPrivateWarrantsBySponsor	5753	usd
CY2023	USCTU	Sale Of Founder Shares And Private Warrant By Sponsor SaleOfFounderSharesAndPrivateWarrantBySponsor	5753	usd
CY2023	USCTU	Capital Contribution From Forgiveness Of Related Party Expenses CapitalContributionFromForgivenessOfRelatedPartyExpenses	60556	usd
CY2023	USCTU	Capital Contribution From Wejo Assignment And Assumption Agreement CapitalContributionFromWejoAssignmentAndAssumptionAgreement	250000	usd
CY2023	USCTU	Capital Contribution From Working Capital Advance CapitalContributionFromWorkingCapitalAdvance	250000	usd
CY2023	USCTU	Capital Contribution From Commitment Fee CapitalContributionFromCommitmentFee	125000	usd
CY2023	USCTU	Reduction Of Deferred Underwriting Fee ReductionOfDeferredUnderwritingFee	8231688	usd
CY2023	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-2869662	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2586752	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1847814	usd
CY2023	us-gaap	Profit Loss ProfitLoss	2586752	usd
CY2022	us-gaap	Profit Loss ProfitLoss	11245341	usd
CY2023	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	2509662	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	3383885	usd
CY2023	USCTU	Forgiveness Of Debt ForgivenessOfDebt	4692176	usd
CY2023	us-gaap	Interest Expense InterestExpense	125000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	73425	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10197175	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-297934	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-403425	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3263737	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1326054	usd
CY2023	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts	8000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-862990	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-606240	usd
CY2023	USCTU	Investment Of Cash Into Trust InvestmentOfCashIntoTrust	360000	usd
CY2023	USCTU	Payments For Redemptions Of Class Ordinary Shares PaymentsForRedemptionsOfClassOrdinaryShares	217525458	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	217165458	usd
CY2023	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts	70000	usd
CY2022	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts	20085	usd
CY2023	USCTU	Advances From Related Party AdvancesFromRelatedParty	341000	usd
CY2023	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	250000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	591508	usd
CY2023	USCTU	Payments For Redemption Of Class Ordinary Shares PaymentsForRedemptionOfClassOrdinaryShares	217525458	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-216412950	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20085	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-110482	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-626325	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124237	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	750562	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13755	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124237	usd
CY2023	USCTU	Reduction Of Deferred Underwriting Fee Payable ReductionOfDeferredUnderwritingFeePayable	8231688	usd
CY2023	USCTU	Forgiveness Of Advances From Related Parties ForgivenessOfAdvancesFromRelatedParties	560556	usd
CY2023	USCTU	Conversion Of Advances And Shortterm Promissory Notes To Longterm Promissory Notes ConversionOfAdvancesAndShorttermPromissoryNotesToLongtermPromissoryNotes	91000	usd
CY2023	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	2869662	usd
CY2022	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	3387827	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zYLBti3PlfFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 — <span id="xdx_823_zcYbXSNlqVvi">Description of Organization and Business Operations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Roth CH Acquisition Co. (the “<span style="text-decoration: underline">Company</span>”) is a blank check company incorporated as a Cayman Islands exempted company on April 20, 2021 with the name TKB Critical Technologies 1. The Company changed its name on September 7, 2023 to Roth CH Acquisition Co. The Company was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “<span style="text-decoration: underline">initial business combination</span>”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not limited to a particular industry or geographic location for purposes of consummating an initial business combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company had not commenced any operations. All activity for the period from April 20, 2021 (inception) through December 31, 2023, relates to the Company’s formation and its initial public offering (the “<span style="text-decoration: underline">IPO</span>”), which is described below and, subsequent to the IPO, identifying a target company for an initial business combination. The Company will not generate any operating revenues until after the completion of the initial business combination, at the earliest. The Company generates non-operating income from the marketable securities held in the Trust Account (defined below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The registration statement for the Company’s IPO was declared effective on October 26, 2021 (the “<span style="text-decoration: underline">Effective Date</span>”). On October 29, 2021, the Company consummated the IPO of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">23,000,000</span> units (the “<span style="text-decoration: underline">Units</span>”), including <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">3,000,000</span> Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of Stock, Price Per Share">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Sale of Stock, Consideration Received on Transaction">230,000,000</span>, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">10,750,000</span> Private Placement Warrants (the “<span style="text-decoration: underline">Private Placement Warrants</span>”) at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.00</span> per Private Warrant in a private placement to TKB Sponsor I, LLC (the “<span style="text-decoration: underline">Sponsor</span>”), generating proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Sale of Stock, Consideration Received on Transaction">10,750,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transaction costs of the IPO amounted to $<span id="xdx_906_ecustom--TransactionCosts_c20211001__20211029_pp0p0" title="Transaction costs">21,140,059</span>, consisting of $<span id="xdx_90A_ecustom--UnderwritingFees_c20211001__20211029_pp0p0" title="Underwriting fees">3,850,000</span> of underwriting discount, $<span id="xdx_90D_ecustom--DeferredUnderwritingFees_c20211001__20211029_pp0p0" title="Deferred underwriting fees">8,800,000</span> of deferred underwriting discount, $<span id="xdx_906_ecustom--ExcessFairValueOfFounderShares_c20211001__20211029_pp0p0" title="Excess fair value of founder shares">7,748,431</span> excess fair value of founder shares and $<span id="xdx_909_ecustom--ActualOfferingCost_c20211001__20211029_pp0p0" title="Actual offering cost">741,628</span> of offering costs. Of these amounts, $<span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20211029_pp0p0" title="Additional paid-in capital">19,774,814</span> was recorded to additional paid-in capital and $<span id="xdx_900_ecustom--WarrantLiabilityCost_c20211001__20211029_pp0p0" title="Warrant liability cost">1,365,245</span> costs related to the warrant liability was expensed immediately using the residual allocation method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the closing of the IPO on October 29, 2021, $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">234,600,000</span> ($<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Shares Issued, Price Per Share">10.20</span> per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “<span style="text-decoration: underline">Trust Account</span>”), located in the United States, which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of an initial business combination; and (ii) the redemption of any Public Shares (as defined below) properly submitted in connection with a shareholder vote to amend the Company’s Amended and Restated Memorandum and Articles of Association (“<span style="text-decoration: underline">Articles</span>”); and (iii) the redemption of the Company’s Public Shares if the Company is unable to complete the initial business combination by October 29, 2024 (or any extended period of time that the Company may have to consummate an initial business combination as a result of an amendment to its Articles) (the “<span style="text-decoration: underline">Combination Period</span>”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating an initial business combination. There is no assurance that the Company will be able to complete an initial business combination successfully. The Company must complete an initial business combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company’s signing a definitive agreement in connection with its initial business combination. The Company will only complete an initial business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “<span style="text-decoration: underline">Investment Company Act</span>”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will provide its holders of the outstanding Public Shares (the “<span style="text-decoration: underline">public shareholders</span>”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of an initial business combination either (i) in connection with a general meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of an initial business combination or conduct a tender offer will be made by the Company. The public shareholder will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.20 per Public Share initially, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations and which interest shall be net of taxes payable), calculated as of two business days prior to the completion of the initial business combination. The per-share amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 8). There will be no redemption rights upon the completion of an initial business combination with respect to the Company’s warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will only proceed with an initial business combination if the Company has net tangible assets of at least $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferredOther1_c20230101__20231231_pp0p0" title="Business Combination, Consideration Transferred, Other">5,000,001</span> either prior to or upon such consummation of an initial business combination and if the Company seeks shareholder approval. If the Company seeks shareholder approval, the Company will complete its initial business combination only if the Company receives approval pursuant to an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company, or (ii) if so authorized by the Company’s Articles, a unanimous written resolution of the shareholders. If a shareholder vote is not required by applicable law or stock exchange rules and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Articles, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “<span style="text-decoration: underline">SEC</span>”) and file tender offer documents with the SEC prior to completing an initial business combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange rules, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with an initial business combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 6), and any Public Shares purchased during or after the IPO in favor of approving an initial business combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the above, if the Company seeks shareholder approval of an initial business combination and it does not conduct redemptions pursuant to the tender offer rules, the Articles provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “<span style="text-decoration: underline">Exchange Act</span>”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Articles of the Company provides that only Public Shares and not any Founder Shares are entitled to redemption rights. In addition, the Sponsor has agreed (a) to waive its redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of an initial business combination and (b) not to propose an amendment to the Articles (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial business combination or to redeem 100% of its Public Shares if the Company does not complete an initial business combination or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is unable to complete an initial business combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $<span id="xdx_90A_ecustom--DissolutionExpenses_c20230101__20231231_pp0p0" title="Dissolution expenses">100,000</span> of interest to pay dissolution expenses, which interest shall be net of taxes payable), divided by the number of then-outstanding Public Shares, which redemption will completely extinguish public shareholders rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Cayman Islands law, to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire as worthless if the Company fails to complete an initial business combination within the Combination Period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares if the Company fails to complete an initial business combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete an initial business combination within the Combination Period. The underwriter has agreed to waive it right to its deferred underwriting commission held in the Trust Account in the event the Company does not complete an initial business combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered (other than its independent registered public accounting firm) or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.20 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case, net of the interest which may be withdrawn to pay franchise and income taxes. This liability will not apply with respect to claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and will not apply as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “<span style="text-decoration: underline">Securities Act</span>”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2023, the Company, entered into a business combination agreement with Wejo Group Limited, an exempted company limited by shares incorporated under the laws of Bermuda (“<span style="text-decoration: underline">Wejo</span>”), and Green Merger Subsidiary Limited, an exempted company incorporated under the laws of the Cayman Islands and a direct, wholly owned subsidiary of Wejo (“<span style="text-decoration: underline">Merger Sub 1</span>”) and upon execution of a joinder to the business combination agreement, each of Wejo Holdings Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned subsidiary of Wejo (“<span style="text-decoration: underline">Holdco</span>”) and Wejo Acquisition Company Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned Subsidiary of Holdco (“<span style="text-decoration: underline">Merger Sub 2</span>” and together with Merger Sub 1) (as it may be amended, restated, supplemented or otherwise modified from time to time, the “<span style="text-decoration: underline">Business Combination Agreement</span>”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 27, 2023, the Company held an extraordinary general meeting (the “<span style="text-decoration: underline">Extraordinary General Meeting</span>”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “<span style="text-decoration: underline">Extension Amendment Proposal</span>”) to amend the Company’s Amended and restated memorandum and articles of association (the “<span style="text-decoration: underline">Articles</span>”) to extend the date that the Company has to consummate a business combination from January 29, 2023 to June 29, 2023 (the “<span style="text-decoration: underline">Extension Amendment</span>”). The shareholders also approved a proposal (the “<span style="text-decoration: underline">Trust Agreement Amendment Proposal</span>”) to amend the Company’s Investment Management Trust Agreement, dated as of October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company as trustee (the “<span style="text-decoration: underline">Trust Agreement</span>”), to make a corresponding extension to the date the Company must commence liquidation of the Trust Account from January 29, 2023, to June 29, 2023. In connection with the vote to approve the Extension Amendment Proposal, the holders of <span id="xdx_90F_ecustom--ClassOrdinaryShares_c20230127_pdd" title="Class A ordinary shares">17,533,296</span> Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_90E_ecustom--OrdinaryStockRedemptionPricePerShare_c20230127_pdd" title="Redemption price">10.38</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_900_ecustom--AggregateRedemptionAmount_iI_pn3n3_dm_c20230127_zLbmZtJjUYOg" title="Aggregate redemption amount">181.9</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 25, 2023, the Company, Wejo, Holdco, Merger Sub 1 and Merger Sub 2 entered into that certain Mutual Termination Agreement (“Termination Agreement”) pursuant to which the parties mutually agreed to terminate the Business Combination Agreement pursuant to Section 7.1(a) thereof. The Termination Agreement also includes mutual releases of the parties. No party will be required to pay a termination fee as a result of the mutual decision to enter into the Termination Agreement. The termination of the Business Combination Agreement also terminates the Voting Agreement, dated as of January 10, 2023 (“Wejo Voting Agreement”) between the Company and certain shareholders of Wejo and the Voting Agreement, dated as of January 10, 2023 (the “Sponsor Voting Agreement”) between the Company, Sponsor and Directors, pursuant to the terms of the Wejo Voting Agreement and Sponsor Voting Agreement, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 25, 2023, the Company, the Sponsor, each independent director of the Company (the “Directors”), and affiliates of Roth Capital Partners and Craig-Hallum Capital Group LLC (the “Buyers”) entered into a Securities Transfer Agreement (the “Agreement”) pursuant to which Sponsor and the Directors have agreed to sell to Buyers, and Buyers have agreed to purchase from Sponsor and the Directors, an aggregate of <span id="xdx_90A_ecustom--ClassOrdinaryShares_c20230625_pdd" title="Class A ordinary shares">4,312,500</span> ordinary shares consisting of <span id="xdx_90E_ecustom--ClassOrdinaryShares_c20230625__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_pdd" title="Class A ordinary shares">4,237,500</span> Class A ordinary shares and <span id="xdx_909_ecustom--ClassOrdinaryShares_c20230625__us-gaap--StatementEquityComponentsAxis__custom--ClassBOrdinarySharesMember_pdd" title="Class A ordinary shares">75,000</span> Class B ordinary shares and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230625_pdd" title="Class of warrant or right, outstanding">8,062,500</span> private placement warrants (together, the “Transferred Securities”) for an aggregate purchase price (the “Purchase Price”) of $<span id="xdx_904_eus-gaap--SharePrice_c20230625_pdd" title="Share price">1.00</span> (the “Transaction”). Following the closing of the Transaction, Sponsor will have certain continuing rights, including a right of first refusal to repurchase the Transferred Securities in certain circumstances as set forth in the Agreement and the right to invest up to 25% of certain financings. The closing of the Transaction is conditioned upon, among other things, (i) the termination of the Business Combination Agreement (as noted above) and the complete release of actual or potential claims or liabilities thereunder, (ii) continued listing of the Company’s Class A ordinary shares on Nasdaq, (iii) the waiver by the underwriters of the Company’s initial public offering of their rights to deferred underwriting compensation pursuant to the Underwriting Agreement dated as of October 26, 2021, between the Company and Jefferies LLC as representative of the underwriters named therein, and (iv) the occurrence of the Class B Conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 26, 2023, the Company entered into a termination agreement (the “Termination Agreement”), pursuant to which the Company terminated the Administrative Services Agreement with Tartavull Klein Blatteis Capital, LLC dated October 26, 2021 and Tartavull Klein Blatteis Capital, LLC forgave and fully discharged all outstanding fees thereunder as of the date of the Closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2023, the Company held an extraordinary general meeting (the “Second <span style="text-decoration: underline">Extraordinary General Meeting</span>”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “Second <span style="text-decoration: underline">Extension Amendment Proposal</span>”) to amend the Company’s Amended and restated memorandum and articles of association (the “<span style="text-decoration: underline">Articles</span>”) to extend the date that the Company has to consummate a business combination from June 29, 2023 to October 29, 2024 (the “<span style="text-decoration: underline">Extension Amendment</span>”). The shareholders also approved a proposal (the “Second <span style="text-decoration: underline">Trust Agreement Amendment Proposal</span>”) to amend the Company’s <span style="text-decoration: underline">Trust Agreement</span>, to make a corresponding extension to the date by which the Trustee is obligated to liquidate the trust account to the later of (A) June 29, 2023 provided that the Company may extend such date, monthly, up to October 29, 2024 (i.e.: 36 months after the closing of the IPO provided that the Sponsor or its designee deposits the Monthly Deposit (as defined below) into the trust account), or (B) such later date as may be approved by the Company’s shareholders in accordance with the Company’s amended and restated memorandum and articles of association. The term “<span style="text-decoration: underline">Monthly Deposit</span>” is defined in the Amendment to mean an amount equal to the lesser of (x) $<span id="xdx_906_eus-gaap--Deposits_c20230628_pp0p0" title="Aggregate deposit">60,000</span> or (y) $0.03 per public share multiplied by the number of public shares outstanding. In connection with the vote to approve the Second Extension Amendment Proposal, the holders of <span id="xdx_909_ecustom--ClassOrdinaryShares_c20230628_pdd" title="Class A ordinary shares">3,347,468</span> Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_901_ecustom--OrdinaryStockRedemptionPricePerShare_c20230628_pdd" title="Redemption price">10.64</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_909_ecustom--AggregateRedemptionsAmount_iI_pp0p0_c20230628_zbHQzVRwSxP9" title="Aggregate redemptions amount">35,601,649</span>. These shares were effectively canceled on July 7, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity and Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company had $<span id="xdx_90C_eus-gaap--Cash_c20231231_pp0p0" title="Cash">13,755</span> cash and a working capital deficit of $<span id="xdx_90B_ecustom--WorkingCapitalDeficit_c20231231_pp0p0" title="Working capital deficit">1,291,564</span>. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company expects that it will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 27, 2023, the Company’s shareholders approved an amendment to the Articles to extend the end of the Combination Period from January 29, 2023 to June 29, 2023 (the “<span style="text-decoration: underline">Extension</span>”). The shareholders also approved an amendment to the Company’s Investment Management Trust Agreement, dated as of October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company as trustee (the “<span style="text-decoration: underline">Trust Agreement</span>”), to make a corresponding extension to the date the Company must commence liquidation of the Trust Account from January 29, 2023 to June 29, 2023. On January 31, 2023, in connection with the vote to approve the Extension, the holders of <span id="xdx_908_ecustom--ExercisedShares_c20230101__20231231_pdd" title="Exercised Shares">17,533,296</span> Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_902_ecustom--OrdinaryStockRedemptionPricePerShare_iI_c20230127_zchJiqjEgG9k" title="Redemption price">10.38</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_90D_ecustom--AggregateRedemptionAmount_iI_pn3n3_dm_c20230127_zPEGDAbfCGue" title="Aggregate redemption amount">181.9</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2023, the Company held an extraordinary general meeting (the “Second <span style="text-decoration: underline">Extraordinary General Meeting</span>”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “Second <span style="text-decoration: underline">Extension Amendment Proposal</span>”) to amend the Company’s Amended and restated memorandum and articles of association (the “<span style="text-decoration: underline">Articles</span>”) to extend the date that the Company has to consummate a business combination from June 29, 2023 to October 29, 2024 (the “<span style="text-decoration: underline">Extension Amendment</span>”). The shareholders also approved a proposal (the “Second <span style="text-decoration: underline">Trust Agreement Amendment Proposal</span>”) to amend the Company’s <span style="text-decoration: underline">Trust Agreement</span>, to make a corresponding extension to the date by which the Trustee is obligated to liquidate the trust account to the later of (A) June 29, 2023 provided that the Company may extend such date, monthly, up to October 29, 2024 (i.e.: 36 months after the closing of the IPO provided that the Sponsor or its designee deposits the Monthly Deposit (as defined below) into the trust account), or (B) such later date as may be approved by the Company’s shareholders in accordance with the Company’s amended and restated memorandum and articles of association. The term “<span style="text-decoration: underline">Monthly Deposit</span>” is defined in the Amendment to mean an amount equal to the lesser of (x) $<span id="xdx_903_eus-gaap--Deposits_iI_pp0p0_c20230628_zSbvZfcklbQg" title="Aggregate deposit">60,000</span> or (y) $0.03 per public share multiplied by the number of public shares outstanding. In connection with the vote to approve the Second Extension Amendment Proposal, the holders of <span id="xdx_905_ecustom--ClassOrdinaryShares_iI_c20230628_zczHiBsDvDR" title="Class A ordinary shares">3,347,468</span> Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_90A_ecustom--OrdinaryStockRedemptionPricePerShare_iI_c20230628_zgWFqh7pMFol" title="Redemption price">10.64</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_90B_ecustom--AggregateRedemptionsAmount_iI_pp0p0_c20230628_z1oUKgw4t0Dh" title="Aggregate redemptions amount">35,601,649</span>. These shares were effectively canceled on July 7, 2023. As of the date of these financial statements, the Company has deposited an aggregate of $<span id="xdx_90B_eus-gaap--Deposits_iI_c20230629_zMh1PqP0FhQ4" title="Aggregate deposit">540,000</span> into the trust account for a total of Nine Monthly Deposits, thereby extending the Business Combination period to March 29, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Codification (“<span style="text-decoration: underline">ASC</span>”) Topic 205-40, “Basis of Presentation – Going Concern”. The Company has until March 29, 2024 (absent any extensions of such period by the Company’s shareholders) to consummate an initial business combination. While the Company intends to complete a business combination before the mandatory liquidation date, it is uncertain that the Company will be able to consummate an initial business combination by that time. If an initial business combination is not consummated by that date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the liquidity condition and mandatory liquidation, should an initial business combination not occur, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after March 29, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements does not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific impact on the Company’s financial condition, results of operations and cash flows is also not determinable as of the date of these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q4	USCTU	Transaction Costs TransactionCosts	21140059	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Cost ActualOfferingCost	741628	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19774814	usd
CY2021Q4	USCTU	Warrant Liability Cost WarrantLiabilityCost	1365245	usd
CY2023	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	5000001	usd
CY2023	USCTU	Dissolution Expenses DissolutionExpenses	100000	usd
CY2023Q1	USCTU	Class Ordinary Shares ClassOrdinaryShares	17533296	shares
CY2023Q1	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.38
CY2023Q1	USCTU	Aggregate Redemption Amount AggregateRedemptionAmount	181900000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8062500	shares
CY2023Q2	us-gaap	Share Price SharePrice	1.00
CY2023Q2	us-gaap	Deposits Deposits	60000	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	3347468	shares
CY2023Q2	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.64
CY2023Q2	USCTU	Aggregate Redemptions Amount AggregateRedemptionsAmount	35601649	usd
CY2023Q4	us-gaap	Cash Cash	13755	usd
CY2023Q4	USCTU	Working Capital Deficit WorkingCapitalDeficit	1291564	usd
CY2023	USCTU	Exercised Shares ExercisedShares	17533296	shares
CY2023Q1	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.38
CY2023Q1	USCTU	Aggregate Redemption Amount AggregateRedemptionAmount	181900000	usd
CY2023Q2	us-gaap	Deposits Deposits	60000	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	3347468	shares
CY2023Q2	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.64
CY2023Q2	USCTU	Aggregate Redemptions Amount AggregateRedemptionsAmount	35601649	usd
CY2023Q2	us-gaap	Deposits Deposits	540000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zOGZWlx40gIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zVii0oQl5eni">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023Q4	us-gaap	Cash Cash	13755	usd
CY2022Q4	us-gaap	Cash Cash	124237	usd
CY2021Q4	USCTU	Transaction Cost TransactionCost	21140059	usd
CY2021Q4	USCTU	Actual Offering Costs ActualOfferingCosts	741628	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1365245	usd
CY2021Q4	USCTU	Additional Paid In Capitals AdditionalPaidInCapitals	19774814	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_zGwZ1lac6wsg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_z1JRcBeNPXRd">Derivative Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q4	USCTU	Notes Receivable Related Partie NotesReceivableRelatedPartie	20403	usd
CY2023Q3	USCTU	Promissory Note PromissoryNote	1000000	usd
CY2023Q4	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	682508	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	60000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22250000	shares
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zVnAoD3uFi8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_ztKdBuyuWBCk">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage of $<span id="xdx_90A_eus-gaap--FederalFundsSold_c20231231_pp0p0" title="Federal Depository Insurance Coverage">250,000</span>. The Company has not experienced losses on this account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023Q4	us-gaap	Federal Funds Sold FederalFundsSold	250000	usd
CY2021Q4	USCTU	Transaction Costs TransactionCosts	21140059	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Cost ActualOfferingCost	741628	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	4312500	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8062500	shares
CY2023Q2	us-gaap	Share Price SharePrice	1.00
CY2023Q4	USCTU	Outstanding Invoice OutstandingInvoice	31000	usd
CY2023Q4	USCTU	Pay Certain Liabilities PayCertainLiabilities	300000	usd
CY2023Q4	USCTU	Loan Loan	60000	usd
CY2021Q4	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	279597	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	120000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	0	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	100000	usd
CY2023	USCTU	Related Party Loans Description RelatedPartyLoansDescription	The Working Capital Loans would either be repaid upon consummation of an initial business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-business combination entity at a price of $1.00 per warrant.
CY2023Q1	USCTU	Aggregate Principal Amount AggregatePrincipalAmount	750000	usd
CY2023Q1	USCTU	Aggregate Principal Amount AggregatePrincipalAmount	250000	usd
CY2023Q1	USCTU	Business Combination Amount BusinessCombinationAmount	375000	usd
CY2023	USCTU	Commitment Fee CommitmentFee	125000	usd
CY2023	USCTU	Sponsor Description SponsorDescription	the Sponsor an aggregate of $295,000 to fund the Company’s working capital requirements and the Sponsor agreed to assign to Wejo, effective as of the Closing Date or the earlier termination of the Business Combination Agreement in accordance with its terms or otherwise, an aggregate of 83,250 Founder Shares and 250,000 Private Warrants. Wejo paid $250,000 to the Sponsor on January 11, 2023 and $45,000 to the Sponsor on March 2, 2023, for an aggregate payment of $295,000.
CY2023Q4	USCTU	Working Capital WorkingCapital	250000	usd
CY2023Q1	USCTU	Fair Value Of Founder Shares FairValueOfFounderShares	83250	shares
CY2023Q1	USCTU	Fair Value Of Founder Shares Value FairValueOfFounderSharesValue	294289	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0788	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0478	pure
CY2023Q1	USCTU	Closing Price ClosingPrice	0.03
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6789	usd
CY2023Q4	USCTU	Advanced From Sponsor AdvancedFromSponsor	250000	usd
CY2023	USCTU	Sponsor Contribution SponsorContribution	5753	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	USCTU	Sponsor Description SponsorDescription	the Sponsor, the holder of an aggregate of 5,650,000 of the Company’s outstanding Class B ordinary shares, par value $0.0001 per share
CY2023Q2	USCTU	Remaining Converted Shares RemainingConvertedShares	25000	shares
CY2023	USCTU	Share Redemption Price Per Share ShareRedemptionPricePerShare	18.00
CY2021Q4	USCTU	Cash Underwriting Discount CashUnderwritingDiscount	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Commissions DeferredUnderwritingCommissions	8800000	usd
CY2023	USCTU	Deferred Underwriting Commissions DeferredUnderwritingCommissions	8800000	usd
CY2023	USCTU	Aggregate Amount Of Underwriting Commissions AggregateAmountOfUnderwritingCommissions	8800000	usd
CY2023	USCTU	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	0	usd
CY2022	USCTU	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	8800000	usd
CY2021Q3	USCTU	Ordinary Shares OrdinaryShares	45000	shares
CY2022Q3	USCTU	Hourly Payment HourlyPayment	125	usd
CY2022Q4	USCTU	Hourly Payment HourlyPayment	125	usd
CY2023	us-gaap	Sponsor Fees SponsorFees	0	usd
CY2022	us-gaap	Sponsor Fees SponsorFees	191402	usd
CY2023Q4	USCTU	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	0	usd
CY2022Q4	USCTU	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	42181	usd
CY2023Q3	USCTU	Forgiveness Of Debt ForgivenessOfDebt	42181	usd
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16000	usd
CY2023	USCTU	Deferred Legal Fees DeferredLegalFees	2657577	usd
CY2022	USCTU	Deferred Legal Fees DeferredLegalFees	1164402	usd
	USCTU	Deferred Legal Fees DeferredLegalFees	3730114	usd
	USCTU	Deferred Legal Fees DeferredLegalFees	3730114	usd
CY2023Q4	USCTU	Overpayment Amount OverpaymentAmount	147410	usd
CY2023Q4	USCTU	Trust Account Receivable TrustAccountReceivable	147410	usd
CY2023Q4	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.03
CY2022Q4	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.02
CY2023Q1	USCTU	Additional Deposit AdditionalDeposit	60000	usd
CY2023Q1	USCTU	Aggregate Amount AggregateAmount	180000	usd

Files In Submission

Name	View Source	Status
0001829126-24-002417-index-headers.html	Edgar Link	pending
0001829126-24-002417-index.html	Edgar Link	pending
0001829126-24-002417.txt	Edgar Link	pending
0001829126-24-002417-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rothchacq_10k.htm	Edgar Link	pending
rothchacq_ex31-1.htm	Edgar Link	pending
rothchacq_ex31-2.htm	Edgar Link	pending
rothchacq_ex31-3.htm	Edgar Link	pending
rothchacq_ex32-1.htm	Edgar Link	pending
rothchacq_ex32-2.htm	Edgar Link	pending
rothchacq_ex32-3.htm	Edgar Link	pending
rothchacq_ex4-5.htm	Edgar Link	pending
rothchacq_ex97-1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
usctu-20231231.xsd	Edgar Link	pending
usctu-20231231_def.xml	Edgar Link	unprocessable
usctu-20231231_lab.xml	Edgar Link	unprocessable
usctu-20231231_pre.xml	Edgar Link	unprocessable
rothchacq_10k_htm.xml	Edgar Link	completed
usctu-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USCTF
Roth CH Acquisition Co. Stock $usctf

2023 Q4 Form 10-K Financial Statement

#000182912624002417 Filed on April 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF Roth CH Acquisition Co. Stock $usctf

2023 Q4 Form 10-K Financial Statement

#000182912624002417 Filed on April 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF
Roth CH Acquisition Co. Stock $usctf